Featured Research

from universities, journals, and other organizations

Sequential treatment with entecavir and lamivudine results in rebound of hepatitis B virus, study suggests

Date:
March 31, 2011
Source:
Wiley-Blackwell
Summary:
A two-year trial of entecavir followed by lamivudine in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24 percent and 12 percent drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint.

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

The World Health Organization (WHO) estimates that more than 2 billion people worldwide have been infected with HBV; roughly 360 million of these cases are chronic infection that could lead to liver cirrhosis and hepatocelluar carcinoma (liver cancer). LAM is the first oral antiviral agent available to treat chronic HBV infection by inhibiting disease progression. However, a 2007 study by Yuen et al. determined that long-term treatment with LAM is associated with a 76% drug-resistance rate after eight years. In recent years, studies have shown entecavir to be superior to LAM in reducing HBV DNA, with only a 1.2% drug-resistance rate after five years.

In the current trial, James Fung, M.D., and the team led by Professor Man-Fung Yuen, M.D., Ph.D., from The University of Hong Kong, investigated whether initial HBV DNA suppression by the more potent antiviral agent, entecavir, could be maintained by switching to LAM, a less potent and lower-cost antiviral. The potential for drug-resistance and virological rebound with sequential therapy of the two antiviral therapies was also examined. "Most patients with chronic HBV require long-term antiviral treatment and some patients opt to start with LAM therapy for cost-saving reasons. Our aim was to determine the efficacy and drug-resistance profile of switching to LAM after initial entecavir treatment," said Dr. Fung.

Researchers recruited 50 patients with chronic HBV who were all initially treated with entecavir (0.5 mg) for at least six months prior to the start of the study. A normal alanine aminotransferase (ALT) level and undetectable HBV DNA were required for inclusion in the study. Participants were randomized into two arms with patients in the first arm continuing to receive 0.5 mg of entecavir daily and patients in the second arm switching to 100 mg LAM daily. Routine liver biochemistry, hepatitis B serological test, and HBV DNA measurements were performed at 0, 4, 12, 24, 48, 72, and 96 weeks.

Results showed that 100% of patients in the entecavir-only arm continued to have undetectable HBV DNA, while 24% of participants who switched to LAM experienced virological rebound. Researchers noted that virological rebound continues to increase over time as two patients showed an increased in HBV DNA at 96 weeks. Additionally, three patients (12%) developed LAM-resistance. "Prior HBV DNA suppression with entecavir did not offer any significant advantage to patients who switched to LAM," concluded Dr. Fung. "The potential cost-saving benefit of switching to LAM was not realized due to the development of resistance."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. James Fung, Ching-Lung Lai, John Yuen, Charles Cheng, Ringo Wu, Danny Ka-Ho Wong, Wai-Kay Seto, Ivan Fan-Ngai Hung, Man-Fung Yuen. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable HBV DNA: Outcome at 2 years. Hepatology, 2011; DOI: 10.1002/hep.24192

Cite This Page:

Wiley-Blackwell. "Sequential treatment with entecavir and lamivudine results in rebound of hepatitis B virus, study suggests." ScienceDaily. ScienceDaily, 31 March 2011. <www.sciencedaily.com/releases/2011/03/110331114857.htm>.
Wiley-Blackwell. (2011, March 31). Sequential treatment with entecavir and lamivudine results in rebound of hepatitis B virus, study suggests. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2011/03/110331114857.htm
Wiley-Blackwell. "Sequential treatment with entecavir and lamivudine results in rebound of hepatitis B virus, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/03/110331114857.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins